Search Results | MSF Science Portal

Journal Article

|

Research

Sinha A, Klebe R, Rekart ML, Alvarez JL, Skrahina A, et al.

2025-02-18 • Clinical Infectious Diseases

BACKGROUND

Only 63% of patients initiating multidrug-resistant/rifampicin-resistant tuberculosis (MDR/RR-TB) treatment in 2020 were treated successfully. 24-Wee...

Journal Article

|

Research

Garcia-Prats AJ, Garcia-Cremades M, Cox V, Kredo T, Dunbar R, et al.

2025-02-01 • Lancet Child and Adolescent Health

BACKGROUND

There are few data on the treatment of children and adolescents with multidrug-resistant (MDR) or rifampicin-resistant (RR) tuberculosis, especially ...

Journal Article

|

Research

Sweeney S, Laurence YV, Berry C, Singh MP, Dodd M, et al.

2025-02-01 • Lancet Global Health

BACKGROUND

New 6-month rifampicin-resistant tuberculosis treatment regimens containing bedaquiline, pretomanid, and linezolid (BPaL) with or without moxifloxaci...

Journal Article

|

Research

Moe S, Azamat I, Allamuratova S, Oluya M, Khristusev A, et al.

2024-09-01 • IJTLD OPEN

BACKGROUND

Dru...

Journal Article

|

Letter

Crocker-Buque T, Lachenal N, Narasimooloo C, Abdrasuliev T, Parpieva N, et al.

2024-08-15 • Clinical Infectious Diseases

Journal Article

|

Research

Rekart M, Thit P, Oluya M, Moe S, Hasan T, et al.

2024-07-01 • IJTLD OPEN

Background

Isoniazid (INH, H) resistance is the most common drug-resistant TB pattern, with treatment success rates lower than those in drug-susceptible TB. The...

Journal Article

|

Research

Motta I, Cusinato M, Ludman AJ, Lachenal N, Dodd M, et al.

2024-06-06 • Antimicrobial Agents and Chemotherapy

Regimens for the treatment of rifampicin-resistant tuberculosis currently rely on the use of QT-prolonging agents. Using data from the randomized controlled trial, TB-PRACTECAL, we inves...

Journal Article

|

Research

Nyang'wa BT, Berry C, Kazounis E, Motta I, Parpieva N, et al.

2024-02-01 • Lancet Respiratory Medicine

BACKGROUND
Around 500,000 people worldwide develop rifampicin-resistant tuberculosis each year. The proportion of successful treatment outcomes remains low and new treatments are nee...

Conference Material

|

Poster

Motta I, Cusinato M, Ludman A, Abdrasuliev T, Butabekov I, et al.

2023-06-07 • MSF Scientific Day International 2023

Journal Article

|

Research

Nyang'wa BT, Berry C, Kazounis E, Motta I, Parpieva N, et al.

2022-12-22 • New England Journal of Medicine

BACKGROUND
In patients with rifampin-resistant tuberculosis, all-oral treatment regimens that are more effective, shorter, and have a more acceptable side-effect profile than current...

Journal Article

|

Research

Gadoev J, Asadov D, Tillashaykhov M, Tayler-Smith K, Isaakidis P, et al.

2015-06-15 • PLOS One

BACKGROUND
TB is one of the main health priorities in Uzbekistan and relatively high rates of unfavorable treatment outcomes have recently been reported. This requires closer analysi...

Journal Article

|

Research

Abidi S, Achar J, Assao Neino MM, Bang D, Benedetti A, et al.

2020-03-20 • European Respiratory Journal

We sought to compare the effectiveness of two World Health Organization (WHO)-recommended regimens for the treatment of rifampin- or multidrug-resistant (RR/MDR) tuberculosis (TB): a sta...

Journal Article

|

Research

Horter SCB, Stringer B, Gray NSB, Parpieva N, Safaev K, et al.

2020-09-16 • BMC Infectious Diseases

Introduction: Person-centred care, an internationally recognised priority, describes the involvement of people in their care and treatment decisions, and the consideration of their needs...

Journal Article

|

Research

Gil H, Margaryan H, Azamat I, Ziba B, Bayram H, et al.

2021-01-06 • Tropical Medicine and International Health

OBJECTIVES
In this retrospective study, we evaluated the diagnostic accuracy of molecular tests (MT) for the detection of DR‐TB, compared to the gold standard liquid‐based Drug Susce...

Journal Article

|

Research

Bastard M, Sanchez-Padilla E, du Cros PAK, Khamraev AK, Parpieva N, et al.

2018-03-08 • PLOS One

The emergence of resistance to anti-tuberculosis (DR-TB) drugs and the HIV epidemic represent a serious threat for reducing the global burden of TB. Although data on HIV-negative DR-TB t...

Journal Article

|

Research

Stringer B, Lowton K, Tillashaikhov M, Parpieva N, Ulmasova D, et al.

2016-08-01 • International Journal of Tuberculosis and Lung Disease

SETTING
The joint Médecins Sans Frontières/Ministry of Health Multidrug-Resistant Tuberculosis (MDR-TB) Programme, Karakalpakstan, Uzbekistan.

OBJECTIVE
Uzbekistan has h...

Conference Material

|

Abstract

Horter SCB, Stringer B, Gray NSB, Parpieva N, Tigay Z, et al.

2020-05-20 • MSF Scientific Days International 2020

INTRODUCTION
Person-centred care (PCC) is an internationally recognised priority, and a key underlying principle within MSF projects. PCC ensures that people are involved in their ca...

Journal Article

|

Letter

Achar J, Berry C, Herboczek K, Parpieva N, Tillashaykhov M, et al.

2015-09-09 • Emerging Infectious Diseases

Journal Article

|

Research

Gadoev J, Asadov D, Harries AD, Parpieva N, Tayler-Smith K, et al.

2017-05-04 • PLOS One

BACKGROUND
In Uzbekistan, despite stable and relatively high tuberculosis treatment success rates, relatively high rates of recurrent tuberculosis have recently been reported. Recurr...

Journal Article

|

Research

Trauer JM, Achar J, Parpieva N, Khamraev AK, Denholm JT, et al.

2016-11-18 • BMC Medicine

BACKGROUND
Multidrug-resistant tuberculosis (MDR-TB) is a major threat to global TB control. MDR-TB treatment regimens typically have a high pill burden, last 20 months or more and o...

Science Portal

The effectiveness and safety of bedaquiline, pretomanid, and linezolid (BPaL)-based regimens for rifampicin-resistant tuberculosis in non-trial settings - A prospective cohort study in Belarus and Uzbekistan

Characteristics of children and adolescents with multidrug-resistant and rifampicin-resistant tuberculosis and their association with treatment outcomes: a systematic review and individual participant data meta-analysis

24-week, all-oral regimens for pulmonary rifampicin-resistant tuberculosis in TB-PRACTECAL trial sites: an economic evaluation

Second-line drug-resistant TB and associated risk factors in Karakalpakstan, Uzbekistan

Pregnancy outcomes in multidrug-resistant tuberculosis in TB-PRACTECAL

A 10-year review of isoniazid-resistant TB management in Uzbekistan 2009-2020

How much should we still worry about QTc prolongation in rifampicin-resistant tuberculosis? ECG findings from TB-PRACTECAL clinical trial

Short oral regimens for pulmonary rifampicin-resistant tuberculosis (TB-PRACTECAL): an open-label, randomised, controlled, phase 2B-3, multi-arm, multicentre, non-inferiority trial

ECG findings in BPaL-based TB treatment regimens: the geographical effect on QT prolongation

A 24-week, all-oral regimen for rifampin-resistant tuberculosis

Factors associated with unfavorable treatment outcomes in new and previously treated TB patients in Uzbekistan: a five year countrywide study

Standardised shorter regimens versus individualised longer regimens for rifampin- or multidrug-resistant tuberculosis

Person-centred care in practice: perspectives from a short course regimen for multi-drug resistant tuberculosis in Karakalpakstan, Uzbekistan

Accuracy of molecular drug susceptibility testing amongst tuberculosis patients in Karakalpakstan, Uzbekistan

Outcomes of HIV-infected versus HIV-non-infected patients treated for drug-resistance tuberculosis: Multicenter cohort study

'They prefer hidden treatment': anti-tuberculosis drug-taking practices and drug regulation in Karakalpakstan

Person-centred care in practice: perspectives from a short-course regimen for multidrug-resistant tuberculosis in Karakalpakstan, Uzbekistan: qualitative study

Multidrug-Resistant Tuberculosis in Child Successfully Treated with 9-Month Drug Regimen

Recurrent tuberculosis and associated factors: a five-year countrywide study in Uzbekistan

Modelling the effect of short-course multidrug-resistant tuberculosis treatment in Karakalpakstan, Uzbekistan